Mark Coleman Sells 3,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 3,000 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $107.49, for a total value of $322,470.00. Following the sale, the director now owns 54,137 shares of the company’s stock, valued at $5,819,186.13. This trade represents a 5.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $105.76 on Thursday. The stock’s 50-day simple moving average is $109.68 and its 200 day simple moving average is $105.46. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of -17.66 and a beta of 0.46. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analysts’ expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AXSM. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $25,000. NBC Securities Inc. purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $31,000. Quantbot Technologies LP purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $31,000. AlphaQuest LLC purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $38,000. Finally, Neo Ivy Capital Management purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at about $41,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AXSM. Morgan Stanley increased their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Leerink Partners increased their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Wells Fargo & Company reiterated an “overweight” rating and set a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a “buy” rating and set a $153.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, April 1st. Finally, Deutsche Bank Aktiengesellschaft began coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target for the company. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Axsome Therapeutics presently has a consensus rating of “Buy” and an average price target of $172.14.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.